HeartBeam to Discuss Q3 2025 Results and Regulatory Progress in November Conference Call
HeartBeam will host a conference call on November 13, 2025, to discuss third-quarter results and provide updates on its FDA-cleared 3D ECG technology that could transform remote cardiac monitoring.
HeartBeam (NASDAQ: BEAT) will hold a conference call on Thursday, November 13, 2025, at 4:30 p.m. ET to discuss its third quarter results for the period ended September 30, 2025. The medical technology company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones during the call. A detailed press release containing financial and operational details will be issued prior to the conference call, available at https://ibn.fm/5mXsb.
The conference call represents a significant opportunity for investors and healthcare stakeholders to understand HeartBeam's progress in transforming cardiac care through its innovative technology platform. The company is developing the first-ever cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing these signals into a 12-lead ECG. This breakthrough technology could fundamentally change how cardiac conditions are detected and monitored outside traditional medical facilities.
HeartBeam's technology platform is designed for portable devices that can be used wherever patients are located, delivering actionable heart intelligence directly to physicians. This capability enables healthcare providers to identify cardiac health trends and acute conditions while directing patients to appropriate care without requiring hospital visits. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, marking a critical regulatory milestone. The 12-Lead ECG synthesis software component remains under FDA review, representing the next important regulatory hurdle.
The company's intellectual property portfolio includes over 20 issued patents related to technology enablement, providing substantial protection for its innovative approach to cardiac monitoring. Investors can access the latest news and updates relating to BEAT through the company's newsroom at https://ibn.fm/BEAT. The forward-looking nature of the company's statements involves risks and uncertainties that investors should consider, including factors beyond management's control as detailed in SEC filings available through standard regulatory channels.
This development matters because HeartBeam's technology addresses critical gaps in cardiac care accessibility and monitoring. The ability to capture comprehensive ECG data outside clinical settings could significantly improve early detection of cardiac events and enable more continuous monitoring for at-risk patients. As healthcare continues shifting toward remote and home-based care models, technologies like HeartBeam's 3D ECG platform represent the future of cardiac health management. The upcoming conference call will provide crucial insights into how close the company is to bringing this transformative technology to market and scaling its commercial operations.